Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.

[1]  A. El-Khoueiry,et al.  Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer , 2018, Cancer Chemotherapy and Pharmacology.

[2]  Yi-long Wu,et al.  Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  L. Sequist,et al.  OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI , 2017 .

[4]  M. Varella‐Garcia,et al.  Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Yi-long Wu,et al.  Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[6]  C. Paweletz,et al.  Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. , 2016, Cancer discovery.

[7]  L. Sequist,et al.  Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Ash A. Alizadeh,et al.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.

[9]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[10]  Barry S Taylor,et al.  Genomic and biological characterization of exon 4 KRAS mutations in human cancer. , 2010, Cancer research.